Jakavi 10mg Tablet

About

Ruxolitinib, marketed as Jakavi, is a targeted oral therapy that functions as a potent and selective inhibitor of Janus kinase (JAK) 1 and JAK2. These kinases play a crucial role in the signaling pathways of various cytokines and growth factors, which are often dysregulated in myeloproliferative neoplasms such as myelofibrosis and polycythemia vera. By blocking JAK1 and JAK2, ruxolitinib effectively mitigates the symptoms and disease progression associated with these conditions, including reducing spleen size, alleviating constitutional symptoms like fatigue, pruritus, and night sweats, and improving overall quality of life.

Its therapeutic impact stems from its ability to interrupt the aberrant signaling that drives the proliferation of abnormal blood cells and the inflammatory processes characteristic of these diseases. This targeted approach has significantly improved outcomes for patients who previously had limited treatment options, offering a more effective and tolerable management strategy.

Uses

• Treatment of intermediate or high-risk myelofibrosis.
• Management of polycythemia vera in patients who are resistant or intolerant to hydroxyurea.
• Reduction of splenomegaly and improvement of symptoms in myelofibrosis.
• Alleviation of disease-related symptoms in polycythemia vera.

Directions For Use

Take this medication orally, usually twice daily, with or without food. Adhere strictly to your doctor's prescribed dosage and schedule.

Benefits

• Significantly reduces spleen volume in myelofibrosis and polycythemia vera.
• Effectively controls debilitating symptoms such as fatigue, itching, and night sweats.
• Improves overall survival in patients with myelofibrosis.
• Offers a targeted treatment by inhibiting JAK1 and JAK2.
• Enhances quality of life for patients with myeloproliferative neoplasms.
• Provides an oral, convenient treatment option for chronic conditions.

Side Effects

• Thrombocytopenia (low platelet count)
• Anemia (low red blood cell count)
• Neutropenia (low white blood cell count)
• Bruising
• Dizziness
• Headache
• Diarrhea
• Weight gain
• Fatigue
• Urinary tract infection
• Herpes zoster reactivation
• Elevated cholesterol levels

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake, especially if liver function is a concern.
• Pregnancy - Ruxolitinib is not recommended during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - It is advised to avoid breastfeeding during treatment with ruxolitinib and for a period after the last dose, due to potential excretion into breast milk.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments are often necessary, and liver function should be monitored regularly.
• Kidney - Dose adjustments are required for patients with moderate to severe renal impairment or end-stage renal disease. Renal function should be monitored.
• Lung - Monitor for new or worsening respiratory symptoms, as serious infections, including tuberculosis, can occur due to immunosuppression.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.